K-Cap records over 80% eradication rate in all dose groups...European Society of Gastroenterology Announces Clinical Results of Helicobacter Eradication

Oct 15, 2025

K-Cap records over 80% eradication rate in all dose groups...European Society of Gastroenterology Announces Clinical Results of Helicobacter Eradication



The results of the Helicobacter pylori eradication clinical trial of HKINOEN's new drug for gastroesophageal reflux disease 'KCap' (component name: Tegoprazan) were announced at the '2025 European Society of Gastroenterology (UEGW)' held in Berlin, Germany from the 4th to the 7th (local time).

The clinical trial of 382 Helicobacter-positive patients in Korea compared the safety and efficacy of the two drugs after 14 days of administration of standard three-drug therapy (tegoprazan, amoxicillin, and clarithromycin), including P-CAB-based drug K-cap (tegoprazan), and standard three-drug therapy (lansoprazole, amoxicillin, and clarithromycin), including PPI-based drug Lansoprazole.

As a result of the clinical trial, the eradication rates of the 50 mg and 100 mg administration groups of K-cap tablets were 85.95% and 85.48%, respectively, exceeding the eradication rate of 78.74% in the 30 mg administration group of lansoprazole, demonstrating non-inferiority (mITT analysis group). In particular, K-cap recorded a eradication rate of 80% or more in all dose groups, confirming its potential as a first-line treatment for Helicobacter pylori eradication.




The standard three-drug therapy currently used in the first-line treatment of Helicobacter pylori eradication is a double-daily dose of PPI drug and 1 g of the antibiotics amoxicillin and 500 mg of clarithromycin. According to the 'Amendment to the Evidence-Based Clinical Care Guidelines for Treatment of Helicobacter pylori Infection in Koreans' published in 2020, it can be recommended as a first-line treatment therapy only when the eradication rate is at least 80%.

In addition to the results of domestic clinical trials related to Helicobacter pylori eradication treatment, the results of K-Cap's global researcher-led clinical trials in Latin America were also announced.

According to an HKINOEN official, "This clinical result shows that K-Cap can replace existing PPI-based drugs in the first-line treatment of Helicobacter pylori eradication" and "We will further strengthen K-Cap's position in domestic and international markets through various studies in the future.""






This article was translated by Naver AI translator.